Meeting
2020 ASCO Virtual Scientific Program
Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort.
Authors
Michael Nathenson
Department of Medical Oncology; Dana-Farber Cancer Institute, Boston, MA
Michael Nathenson , Edwin Choy , Neena D Carr , Hayley D Hibbard , Emanuele Mazzola , Paul J. Catalano , Katherine Anne Thornton , Jeffrey A. Morgan , Gregory Michael Cote , Priscilla Merriam , Andrew J. Wagner , George D. Demetri , Suzanne George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03899805
Citation
J Clin Oncol 38: 2020 (suppl; abstr 11559)
DOI
10.1200/JCO.2020.38.15_suppl.11559
Abstract #
11559
Poster Bd #
447
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
First Author: Benjamin Adam Weinberg
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2023 ASCO Annual Meeting
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
First Author: Bernard Doger de Spéville
Poster
2023 ASCO Annual Meeting
Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).
First Author: Christophe Le Tourneau